Gritstone Bio ROE 2017-2024 | GRTSQ
Current and historical return on equity (ROE) values for Gritstone Bio (GRTSQ) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Gritstone Bio ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-06-30 |
$-0.13B |
$0.02B |
-325.93% |
| 2024-03-31 |
$-0.14B |
$0.01B |
-230.40% |
| 2023-12-31 |
$-0.14B |
$0.05B |
-146.42% |
| 2023-09-30 |
$-0.14B |
$0.07B |
-111.29% |
| 2023-06-30 |
$-0.13B |
$0.11B |
-93.02% |
| 2023-03-31 |
$-0.13B |
$0.14B |
-81.70% |
| 2022-12-31 |
$-0.12B |
$0.17B |
-72.73% |
| 2022-09-30 |
$-0.12B |
$0.14B |
-67.52% |
| 2022-06-30 |
$-0.12B |
$0.16B |
-60.31% |
| 2022-03-31 |
$-0.11B |
$0.19B |
-56.57% |
| 2021-12-31 |
$-0.08B |
$0.22B |
-37.41% |
| 2021-09-30 |
$-0.07B |
$0.21B |
-38.25% |
| 2021-06-30 |
$-0.07B |
$0.18B |
-45.38% |
| 2021-03-31 |
$-0.07B |
$0.20B |
-53.18% |
| 2020-12-31 |
$-0.11B |
$0.17B |
-93.33% |
| 2020-09-30 |
$-0.11B |
$0.07B |
-101.68% |
| 2020-06-30 |
$-0.11B |
$0.10B |
-86.23% |
| 2020-03-31 |
$-0.10B |
$0.12B |
-70.19% |
| 2019-12-31 |
$-0.10B |
$0.13B |
-62.91% |
| 2019-09-30 |
$-0.08B |
$0.16B |
-54.28% |
| 2019-06-30 |
$-0.08B |
$0.18B |
-55.97% |
| 2019-03-31 |
$-0.07B |
$0.13B |
-77.97% |
| 2018-12-31 |
$-0.06B |
$0.15B |
-115.32% |
| 2018-06-30 |
$-0.04B |
$0.00B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
